|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Merck & Co., Inc. (MRK) Release: FDA Approves PROQUAD(R), The First And Only Vaccine In The U.S. To Help Protect Children Against Measles, Mumps, Rubella And Chickenpox In One Shot
10/19/2005 5:09:14 PM
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Sept. 6, 2005--Merck & Co., Inc. today announced that the U.S. Food and Drug Administration has approved the Company's combination vaccine PROQUAD(R) (Measles, Mumps, Rubella and Varicella (Oka/Merck) Virus Vaccine Live) for simultaneous vaccination against measles, mumps, rubella (German measles) and varicella (chickenpox) in children 12 months to 12 years of age. PROQUAD is the first and only vaccine approved in the United States to help protect against these four diseases in a single shot. PROQUAD is also approved for use in children 12 months to 12 years of age if a second dose of measles, mumps, and rubella vaccine is to be administered.
|
|
|
|
|
|
|
|
|
|
|